The Week in Review #40

 
Conquering NASH
Gilead and Novo Nordisk Conquering NASH

  • What was Gilead Sciences' (GILD) announcement at EASL?
  • What is Gilead doing to find effective treatments for NASH?
  • Why would Novo Nordisk's (NVO) anti-diabetes GLP-1 receptor drug fit as part of a combination for NASH treatment?
  • Is there any Proof of concept offered for any of the combination therapies?
  • What percentage of patients had . . .
    This content is for paid subscribers.
    Please click here to subscribe or here to log in.